Using Continuous Glucose Monitoring to Understand Diabetes Risk and Treatment After Acute Pancreatitis An Observational Study by the Type 1 Diabetes in Acute Pancreatitis Consortium

What this Trial Is About

Researchers are investigating how continuous glucose monitoring CGM can help predict the risk of developing diabetes mellitus DM and prediabetes mellitus PDM following an episode of acute pancreatitis AP. The study also aims to assess whether CGM can provide insights into the need for insulin therapy in those who develop diabetes after AP and explore the underlying mechanisms and diabetes subtypes related to this condition. This observational cohort study is part of the Type 1 Diabetes in Acute Pancreatitis Consortium T1DAPC. Participants will undergo blinded CGM at scheduled visits at 3, 12, 24 months, and annually thereafter to collect glucose data. The study will analyze standard CGM metrics such as mean glucose levels, time spent in specific glucose ranges, and glucose variability to predict diabetes onset and the need for insulin treatment. Additional tests like oral glucose tolerance tests OGTT, mixed meal tolerance tests MMT, and frequently sampled intravenous glucose tolerance tests FSIGTT will be performed to evaluate insulin secretion and resistance. During the study, participants will be assessed through metabolic tests and case report forms, including telephone interviews and longitudinal follow-ups over a 36-month period. Researchers will measure the incidence of prediabetes and diabetes, insulin therapy initiation, and glucose-related metabolic parameters at various time points. The study will provide detailed monitoring to understand glucose patterns and diabetes development after AP, with safety and scientific integrity maintained throughout.

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics